The answer to this SLE question involves a complex decision-making process and is such an important question to answer! I apologize in advance for the long answer. I am in the camp of achieving remission in my SLE patients and getting them off prednisone in the safest ways possible (van Vollenh...

I think of anifrolumab particularly for patients with cutaneous disease. The TULIP-2 trial showed promise for anifrolumab in these patients as a secondary endpoint. In patients with at least moderately active skin disease, 49% of patients achieved >= 50% reduction in CLASI compared to 25% in the ...